Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: A pilot study

Table 2 Time intensity curve

						Variation
		V0	VImax	TPI	PI	PI	TPI
SonoVue
Sorafenib 1	0W	-44.8	-22.3	1.00	24.5
	2W	-48.3	-13.6	3.40	34.7	1.4	3.4
Sorafenib 2	0W	-45.5	-19.6	0.27	25.8
	2W	-48.4	-35.3	0.87	13.1	0.51	3.2
Sorafenib 3	0W	-49.6	-43.7	1.00	5.9
	2W	-49.1	-16.8	1.13	32.3	5.5	1.1
Sorafenib 4	0W	-39.6	-14.9	0.86	24.7
	2W	-45.6	-18.8	4.14	26.8	1.1	4.8
Control 1	0W	-46.4	-25.0	2.00	21.5
	2W	-45.3	-8.7	1.13	36.6	1.7	0.57
Control 2	0W	-48.5	-14.6	2.53	34.0
	2W	-47.8	-16.0	2.60	31.8	0.94	1.0
Control 3	0W	-46.9	-12.4	2.07	34.4
	2W	-49.0	-18.1	2.93	30.9	0.90	1.4
Control 4	0W	-49.9	-37.2	1.06	12.7
	2W	-50.0	-28.5	1.47	21.5	1.7	1.4
Sonazoid
Sorafenib 1	0W	-49.1	-21.9	2.27	27.2
	2W	-48.1	-13.5	3.67	34.5	1.3	1.6
Sorafenib 2	0W	-47.8	-21.4	1.00	26.3
	2W	-49.7	-19.0	2.13	30.7	1.2	2.1
Sorafenib 3	0W	-34.5	-19.1	2.60	15.4
	2W	-47.9	-10.0	2.67	37.9	2.5	1.0
Sorafenib 4	0W	-35.8	-13.0	1.33	22.8
	2W	-41.8	-9.5	4.20	32.3	1.4	3.2
Control 1	0W	-42.5	-16.2	2.33	26.3
	2W	-48.6	-13.0	2.80	35.6	1.4	1.2
Control 2	0W	-37.8	-7.4	4.27	30.4
	2W	-44.0	-12.8	1.80	31.2	1.0	0.42
Control 3	0W	-41.7	-14.7	1.60	27.0
	2W	-49.2	-18.0	2.14	31.2	1.2	1.3
Control 4	0W	-46.7	-27.7	2.87	18.9
	2W	-49.8	-23.7	1.60	26.1	1.4	0.56

TPI: Time to peak intensity.